I don't think amgen's T-vec is a "true" cancer vaccine to compare it to dc vax L. Using oncolytic viruses is a different approach to eradicating cancer and there is no rush for FDA to approve T-vec for melanoma now that CI are already approved for melanoma and showed better results. The "real"catalyst to watch for in cancer vaccine would be the ASCO presentation by CLDX on Rintega in rGBM final results to see if it supports it getting AA by 2016. The interim showed a nice surprise of SS difference compared to Avastin alone in both the PFS and OS.